Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Y0001516

Rivastigmine hydrogen tartrate

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C14H22N2O2 · C4H6O6
Número CAS:
129101-54-8
Peso molecular:
400.42
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

rivastigmine

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

chave InChI

GWHQHAUAXRMMOT-RWALOXMOSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0001485

Rivastigmine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001515

Rivastigmine impurity D, European Pharmacopoeia (EP) Reference Standard

1604811

Rivastigmine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1604836

Rivastigmine, United States Pharmacopeia (USP) Reference Standard

1604825

Rivastigmine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1604847

Rivastigmine tartrate R-isomer, United States Pharmacopeia (USP) Reference Standard

1604869

Rivastigmine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1604858

Rivastigmine tartrate, United States Pharmacopeia (USP) Reference Standard

1604870

Rivastigmine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1604961

Rivastigmine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1604950

Rivastigmine Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR2034

Rivastigmine Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2032

Rivastigmine Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2031

Rivastigmine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2029

Rivastigmine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2033

Rivastigmine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2030

Rivastigmine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

Skull and crossbonesEnvironment
GHS06,GHS09

Palavra indicadora

Danger

Frases de perigo

H300,H411

Classificações de perigo

Acute Tox. 2 Oral - Aquatic Chronic 2

Código de classe de armazenamento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Cassandra Richardson et al.
International journal of geriatric psychiatry, 28(12), 1312-1317 (2013-04-16)
A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of AChEIs on blood
Zhen-Zhen Yang et al.
International journal of pharmaceutics, 452(1-2), 344-354 (2013-05-18)
Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated with cholinergic neurons degeneration. The blood-brain barrier (BBB) not only provides protection for the brain but also hinders the treatment and diagnosis of this neurological disease, because the drugs must
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica